



FOR IMMEDIATE RELEASE

CMD BIOSCIENCE ANNOUNCED TODAY IT IS EXHIBITING AT THE 22nd AMERICAN PEPTIDE SYMPOSIUM IN SAN DIEGO, CALIFORNIA FROM JUNE 25-30.

New Haven, CT June 22nd, 2011: CMDBioscience announced today that they will exhibit at the 22nd American Peptide Symposium in San Diego, CA. The company will introduce CMDInventusSM, their proprietary computational discovery platform aimed at discovering novel peptide candidates.

CMDInventusSM offers pharmaceutical, biotech and life science companies a ground breaking tool to assist with their peptide discovery projects. CMDInventusSM has been fully validated by multiple research projects, including a project aimed at identifying novel dengue virus anti-infective agents. CMDBioscience scientists used CMDInventusSM to interrogate a key dengue viral protein structural motif and rationally design small peptides that bound to the motif. The project, completed in seven weeks time, involved the explicit consideration of 480,000 peptide sequences and ultimately converged on the 27 most promising peptides. Subsequent synthesis and experimental testing revealed excellent anti-infective activity for 5 of the designed peptides.

"In keeping with this year's theme of "Building Bridges" we intend to showcase the benefit of applying our proven computational tools to address the bottleneck of identifying novel peptide candidates for our partner companies. By leveraging the computational discovery platform offered by CMDInventusSM false positives can be weeded out and relevant peptide leads can be identified with fewer resources in a significantly shorter time period." Said Mark Jarosinski, PhD, Director of Business Development for CMDBioscience.

CMDBioscience will exhibit at booth # 40. We will present two posters at the symposium demonstrating the successful validation of CMDInventusSM and reporting our results for an internal discovery project aimed at identifying novel candidates for NAPP-DR6, a target for Alzheimer's Disease.

"Our poster presentations will detail specific milestone results we generated using CMDInventusSM for both an internal discovery project and novel projects of partner organizations." Said Mark Jarosinski. "We are confident that CMDInventusSM is a novel enabling technology in the field of peptide discovery, and intend to highlight that at this year's conference".

About: CMDBioscience is a computational biotechnology company that specializes in the computer-enabled analysis, modeling and design of therapeutic protein-peptide interactions or structure-based peptide design. Using structure-based peptide design, CMD scientists can help partner organizations efficiently identify novel peptide hits and leads, understand the structural basis of protein-peptide interactions, and rationally optimize peptide leads.

CMD Bioscience contact:

www.cmdbioscience.com

Mark Jarosinski, PhD

Director, Business Development

mark.jarosinski@cmdbioscience.com

Phone 317-313-9713